{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:00:00Z","timestamp":1781708400316,"version":"3.54.5"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006318","name":"Universidad Carlos III de Madrid","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006318","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Recessive dystrophic epidermolysis bullosa (RDEB) is a devastating genodermatosis caused by biallelic\n                      <jats:italic>COL7A1<\/jats:italic>\n                      mutations, where chronic inflammation drives disabling complications affecting quality of life and survival. Effective inflammatory control remains a major unmet need. While systemic administration of mesenchymal stromal cells (MSC) from various sources has proven safe with transient benefits yet only one recent placebo-controlled study in RDEB. Consistent type VII collagen (C7) deposition is lacking, and therapeutic mechanisms and predictive biomarkers remain undefined. The MesenSistem-EB trial evaluated for the first time the use of haploidentical BM-MSC and extensively explored their anti-inflammatory potential as a monotherapy in RDEB.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Phase I\/II, single-center, open-label trial, in which nine children with severe RDEB were recruited and eight completed the study after three intravenous infusions of haploidentical BM-MSC (2\u20133\u00d710\n                      <jats:sup>6<\/jats:sup>\n                      cells\/kg) at 21-day intervals. Safety, clinical and patient-reported outcomes, systemic inflammatory mediators and peripheral blood immune profiles were assessed over 12 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MSC therapy was well-tolerated without serious adverse events. Long-term pruritus, sleep and fatigue were globally reduced. In 7\/8 patients at least one key domain significantly improved (disease severity, pruritus, or inflammation) with five classified as good responders. Global median CRP and fibrinogen levels remained stable throughout the study period. Responses correlated with sCD40L and MCP1 dynamics. Flow cytometry revealed altered circulating myeloid and lymphoid compartments at baseline. Post-infusion, immune cell subset changes did not consistently distinguish responders while typically including increased CLA expression on monocytes, partial recovery of memory CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and disappearance of an aberrant granulocyte population, potentially linked to immature myeloid mobilization driven by chronic inflammation. Haploidentical MSC did not consistently confer durable engraftment or sustained C7 deposition.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>BM-MSC is a safe and potentially effective anti-inflammatory intervention that mitigates the expected escalation of systemic inflammatory markers during a critical phase of RDEB progression. MCP1 and sCD40L modulation, with both potentially serving as predictive biomarkers. MSC appear to exert both shared and patient-specific immunomodulatory effects depending on baseline inflammatory cues. Findings provide insights into individual variability, underlying mechanisms and potential therapeutic responsiveness, supporting their use also as a complementary strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:related-object>\n                      <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link>\n                      , identifier NCT04153630.\n                    <\/jats:related-object>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1789537","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:17:08Z","timestamp":1777954628000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics"],"prefix":"10.3389","volume":"17","author":[{"given":"Roc\u00edo","family":"Maseda","sequence":"first","affiliation":[{"name":"Department of Dermatology, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carmen","family":"Arriba","sequence":"additional","affiliation":[{"name":"U714-CIBERER (Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras)","place":["Madrid, Madrid, Spain"]},{"name":"Department of Bioengineering, Universidad Carlos III de Madrid (UC3M)","place":["Madrid, Spain"]},{"name":"Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT), Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Mart\u00ednez-Santamar\u00eda","sequence":"additional","affiliation":[{"name":"U714-CIBERER (Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras)","place":["Madrid, Madrid, Spain"]},{"name":"Department of Bioengineering, Universidad Carlos III de Madrid (UC3M)","place":["Madrid, Spain"]},{"name":"Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT), Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM)","place":["Madrid, Spain"]},{"name":"Spanish Network of Advanced Therapies by TERAV-ISCIII","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Cell Biology Department, Faculty of Medicine, Complutense University","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Herr\u00e1iz-Gil","sequence":"additional","affiliation":[{"name":"U714-CIBERER (Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras)","place":["Madrid, Madrid, Spain"]},{"name":"Department of Bioengineering, Universidad Carlos III de Madrid (UC3M)","place":["Madrid, Spain"]},{"name":"Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT), Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Illera","sequence":"additional","affiliation":[{"name":"U714-CIBERER (Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras)","place":["Madrid, Madrid, Spain"]},{"name":"Department of Bioengineering, Universidad Carlos III de Madrid (UC3M)","place":["Madrid, Spain"]},{"name":"Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT), Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Quintana-Castanedo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"U714-CIBERER (Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras)","place":["Madrid, Madrid, Spain"]},{"name":"Department of Bioengineering, Universidad Carlos III de Madrid (UC3M)","place":["Madrid, Spain"]},{"name":"Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT), Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM)","place":["Madrid, Spain"]},{"name":"Spanish Network of Advanced Therapies by TERAV-ISCIII","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Su\u00e1rez-Sancho","sequence":"additional","affiliation":[{"name":"Spanish Network of Advanced Therapies by TERAV-ISCIII","place":["Madrid, Spain"]},{"name":"ATMPs Production Unit-GMP Facility, Gregorio Mara\u00f1\u00f3n General University Hospital, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Y\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Spanish Network of Advanced Therapies by TERAV-ISCIII","place":["Madrid, Spain"]},{"name":"Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energ\u00e9ticas, Medioambientales, y Tecnol\u00f3gicas (CIEMAT)\/Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras (CIBERER-ISCIII), Instituto de Investigaci\u00f3n Sanitaria de la Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"P\u00e9rez-Conde","sequence":"additional","affiliation":[{"name":"Department of Dermatology, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Carretero","sequence":"additional","affiliation":[{"name":"U714-CIBERER (Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras)","place":["Madrid, Madrid, Spain"]},{"name":"Department of Bioengineering, Universidad Carlos III de Madrid (UC3M)","place":["Madrid, Spain"]},{"name":"Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT), Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM)","place":["Madrid, Spain"]},{"name":"Spanish Network of Advanced Therapies by TERAV-ISCIII","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Mart\u00ednez-Queipo","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic and Medical Biosciences, King\u2019s College London","place":["London, United Kingdom"]},{"name":"National Institute for Health and Care Research (NIHR) Biomedical Research Centre, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"de Paz","sequence":"additional","affiliation":[{"name":"IdiPAZ, Hospital La Paz Insititute for Health Research, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Le\u00f3n","sequence":"additional","affiliation":[{"name":"U714-CIBERER (Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras)","place":["Madrid, Madrid, Spain"]},{"name":"Department of Bioengineering, Universidad Carlos III de Madrid (UC3M)","place":["Madrid, Spain"]},{"name":"Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT), Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM)","place":["Madrid, Spain"]},{"name":"Spanish Network of Advanced Therapies by TERAV-ISCIII","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor","family":"Jim\u00e9nez-Yuste","sequence":"additional","affiliation":[{"name":"Coagulopathies and Haemostasis Disorders Group, IdiPaz, Hematology and Haemotherapy Unit, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto M.","family":"Borobia","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, IdiPAZ, La Paz University Hospital, School of Medicine, Autonomous University of Madrid","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngeles","family":"Vicente","sequence":"additional","affiliation":[{"name":"Spanish Network of Advanced Therapies by TERAV-ISCIII","place":["Madrid, Spain"]},{"name":"Cell Biology Department, Faculty of Medicine, Complutense University","place":["Madrid, Spain"]},{"name":"Stem Cells, Immunity and Cancer Group, Health Research Institute Hospital 12 de Octubre (i+ 12)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su M.","family":"Lwin","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic and Medical Biosciences, King\u2019s College London","place":["London, United Kingdom"]},{"name":"National Institute for Health and Care Research (NIHR) Biomedical Research Centre, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"McGrath","sequence":"additional","affiliation":[{"name":"St John\u2019s Institute of Dermatology, School of Basic and Medical Biosciences, King\u2019s College London","place":["London, United Kingdom"]},{"name":"National Institute for Health and Care Research (NIHR) Biomedical Research Centre, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust and King\u2019s College London","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Fern\u00e1ndez-Santos","sequence":"additional","affiliation":[{"name":"Spanish Network of Advanced Therapies by TERAV-ISCIII","place":["Madrid, Spain"]},{"name":"ATMPs Production Unit-GMP Facility, Gregorio Mara\u00f1\u00f3n General University Hospital, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Butta","sequence":"additional","affiliation":[{"name":"Coagulopathies and Haemostasis Disorders Group, IdiPaz, Hematology and Haemotherapy Unit, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Saced\u00f3n","sequence":"additional","affiliation":[{"name":"Spanish Network of Advanced Therapies by TERAV-ISCIII","place":["Madrid, Spain"]},{"name":"Cell Biology Department, Faculty of Medicine, Complutense University","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcela","family":"del R\u00edo","sequence":"additional","affiliation":[{"name":"U714-CIBERER (Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras)","place":["Madrid, Madrid, Spain"]},{"name":"Department of Bioengineering, Universidad Carlos III de Madrid (UC3M)","place":["Madrid, Spain"]},{"name":"Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT), Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM)","place":["Madrid, Spain"]},{"name":"Spanish Network of Advanced Therapies by TERAV-ISCIII","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"de Lucas","sequence":"additional","affiliation":[{"name":"Department of Dermatology, La Paz University Hospital","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Esc\u00e1mez","sequence":"additional","affiliation":[{"name":"U714-CIBERER (Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Raras)","place":["Madrid, Madrid, Spain"]},{"name":"Department of Bioengineering, Universidad Carlos III de Madrid (UC3M)","place":["Madrid, Spain"]},{"name":"Centro de Investigaciones Energ\u00e9ticas, Medioambientales y Tecnol\u00f3gicas (CIEMAT), Health Research Institute-Fundaci\u00f3n Jim\u00e9nez D\u00edaz University Hospital, Universidad Aut\u00f3noma de Madrid (IIS-FJD, UAM)","place":["Madrid, Spain"]},{"name":"Spanish Network of Advanced Therapies by TERAV-ISCIII","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","article-title":"Epidermolysis bullosa","volume":"6","author":"Bardhan","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2024.03.008","article-title":"Beyond the surface: A narrative review examining the systemic impacts of recessive dystrophic epidermolysis bullosa","volume":"144","author":"Popp","year":"2024","journal-title":"J Invest Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/exd.15146","article-title":"Unveiling the value of C-reactive protein as a severity biomarker and the IL4\/IL13 pathway as a therapeutic target in recessive dystrophic epidermolysis bullosa: A multiparametric cross-sectional study","volume":"33","author":"Quintana-Castanedo","year":"2024","journal-title":"Exp Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000003871","article-title":"Bloodstream infection in children with epidermolysis bullosa","volume":"42","author":"Garcia-Espinosa","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.576558","article-title":"Beneficial effect of systemic allogeneic adipose derived mesenchymal cells on the clinical, inflammatory and immunologic status of a patient with recessive dystrophic epidermolysis bullosa: A case report","volume":"7","author":"Maseda","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41467-025-55934-7","article-title":"Systems immunology integrates the complex endotypes of recessive dystrophic epidermolysis bullosa","volume":"16","author":"Hirt","year":"2025","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2010.01.004","article-title":"Infection and colonization in epidermolysis bullosa","volume":"28","author":"Mellerio","year":"2010","journal-title":"Dermatol Clin"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17698","article-title":"Fibroblast activation and abnormal extracellular matrix remodelling as common hallmarks in three cancer-prone genodermatoses","volume":"181","author":"Chacon-Solano","year":"2019","journal-title":"Br J Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/cells9092108","article-title":"Raloxifene and n-acetylcysteine ameliorate TGF-signalling in fibroblasts from patients with recessive dominant epidermolysis bullosa","volume":"9","author":"Aguado","year":"2020","journal-title":"Cells"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad313","article-title":"Gluten-sensitive enteropathy in recessive dystrophic epidermolysis bullosa","volume":"189","author":"Sacedon","year":"2023","journal-title":"Br J Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/s13023-025-04034-2","article-title":"Tissue and systemic inflammation in dystrophic epidermolysis bullosa: A systematic review and meta-analysis","volume":"20","author":"Karakioulaki","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"B12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/jdv.14673","article-title":"Immune response patterns in non-communicable inflammatory skin diseases","volume":"32","author":"Eyerich","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.matbio.2022.06.007","article-title":"Mechanistic interrogation of mutation-independent disease modulators of RDEB identifies the small leucine-rich proteoglycan PRELP as a TGF-beta antagonist and inhibitor of fibrosis","volume":"111","author":"Chacon-Solano","year":"2022","journal-title":"Matrix Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljag082","article-title":"Systemic inflammation in recessive dystrophic epidermolysis bullosa: a five-year longitudinal study","volume":"5","author":"Karakioulaki","year":"2026","journal-title":"Br J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225707","article-title":"Epidermolysis bullosa-associated squamous cell carcinoma: From pathogenesis to therapeutic perspectives","volume":"20","author":"Condorelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.035","article-title":"Epidermolysis bullosa and the risk of life-threatening cancers: The National EB Registry experience, 1986-2006","volume":"60","author":"Fine","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-019-02073-3","article-title":"Epidemiology and natural history of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa patients: 20 years\u2019 experience of a reference centre in Spain","volume":"21","author":"Castelo","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2019.02.023","article-title":"A nutrition-based approach to epidermolysis bullosa: Causes, assessments, requirements and management","volume":"39","author":"Salera","year":"2020","journal-title":"Clin Nutr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015271","article-title":"Interplay between iron metabolism, inflammation, and EPO-ERFE-Hepcidin axis in RDEB-associated chronic anemia","volume":"9","author":"Quintana-Castanedo","year":"2025","journal-title":"Blood Adv"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.500","article-title":"Peripheral neuro-immune pathology in recessive dystrophic epidermolysis bullosa","volume":"135","author":"Mack","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx069","article-title":"Recessive dystrophic epidermolysis bullosa results in painful small fibre neuropathy","volume":"140","author":"von Bischhoffshausen","year":"2017","journal-title":"Brain"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19496","article-title":"Prevalence, pathophysiology and management of itch in epidermolysis bullosa","volume":"184","author":"Papanikolaou","year":"2021","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13023-021-01811-7","article-title":"A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa","volume":"16","author":"Tang","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s13023-022-02419-1","article-title":"Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: A costing and health-related quality of life study","volume":"17","author":"Angelis","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S386923","article-title":"Innovations in the treatment of dystrophic epidermolysis bullosa (DEB): Current landscape and prospects","volume":"19","author":"Hou","year":"2023","journal-title":"Ther Clin Risk Manag"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206663","article-title":"Trial of Beremagene Geperpavec (B-VEC) for dystrophic epidermolysis bullosa","volume":"387","author":"Guide","year":"2022","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s13023-022-02546-9","article-title":"Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa","volume":"17","author":"So","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.03.073","article-title":"VYJUVEK for dystrophic epidermolysis bullosa: Ethical dilemmas in access and pricing","volume":"94","author":"Islam","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s13287-024-03885-z","article-title":"Translational potential of mesenchymal stem cells in regenerative therapies for human diseases: Challenges and opportunities","volume":"15","author":"Zhidu","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/dth.12305","article-title":"Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: A randomized controlled trial","volume":"29","author":"El-Darouti","year":"2016","journal-title":"Dermatol Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.038","article-title":"Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa","volume":"83","author":"Rashidghamat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2419931","article-title":"Systemic treatment of recessive dystrophic epidermolysis bullosa with mesenchymal stromal cells: A scoping review of the literature and conclusions for future clinical research","volume":"35","author":"Niebergall-Roth","year":"2024","journal-title":"J Dermatolog Treat"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20225680","article-title":"The importance of HLA assessment in \u201coff-the-shelf\u201d allogeneic mesenchymal stem cells based-therapies","volume":"20","author":"Kot","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18128","article-title":"Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa","volume":"182","author":"Has","year":"2020","journal-title":"Br J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2019.100249","article-title":"Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis","volume":"19","author":"Thompson","year":"2020","journal-title":"EClinicalMedicine"},{"key":"B38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13287-022-02751-0","article-title":"Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: A systematic review","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jaad.2013.09.041","article-title":"Development, reliability, and validity of a novel Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI)","volume":"70","author":"Loh","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09041.x","article-title":"The Birmingham Epidermolysis Bullosa Severity score: Development and validation","volume":"160","author":"Moss","year":"2009","journal-title":"Br J Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2011.07.005","article-title":"Validity of four pain intensity rating scales","volume":"152","author":"Ferreira-Valente","year":"2011","journal-title":"Pain"},{"key":"B42","first-page":"9","article-title":"Pain in children: Comparison of assessment scales","volume":"14","author":"Wong","year":"1988","journal-title":"Pediatr Nurs"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2011.04.007","article-title":"Measurement of itching: validation of the leuven itch scale","volume":"37","author":"Haest","year":"2011","journal-title":"Burns"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2012.11.011","article-title":"Spanish transcultural adaptation of the Leuven Itch Scale","volume":"39","author":"Yuste","year":"2013","journal-title":"Burns"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/BCR.0b013e3182372bfa","article-title":"Itch assessment scale for the pediatric burn survivor","volume":"33","author":"Morris","year":"2012","journal-title":"J Burn Care Res"},{"key":"B46","unstructured":"The pedsQL measurement model for pediatric quality of life inventory\n          \n          \n            \n              Varni\n              JW\n            \n          \n          \n          2025"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09713.x","article-title":"The first COL7A1 mutation survey in a large Spanish dystrophic epidermolysis bullosa cohort: c.6527insC disclosed as an unusually recurrent mutation","volume":"163","author":"Escamez","year":"2010","journal-title":"Br J Dermatol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.4097\/kjae.2017.70.4.407","article-title":"Statistical data preparation: Management of missing values and outliers","volume":"70","author":"Kwak","year":"2017","journal-title":"Korean J Anesthesiol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2021.04.006","article-title":"Epidermolysis bullosa in Spain: Observational study of a cohort of patients treated in a national referral center","author":"Maseda Pedrero","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"jmg-2025-110967","DOI":"10.1136\/jmg-2025-110967","article-title":"Sephardic origins revealed for rare skin disorder, recessive dystrophic epidermolysis bullosa, in individuals carrying the unique c.6527insC mutation","author":"Warshauer","year":"2025","journal-title":"J Med Genet"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13953","article-title":"The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): Grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa","volume":"31","author":"Jain","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.893365","article-title":"N-glycosylation and inflammation; the not-so-sweet relation","volume":"13","author":"Radovani","year":"2022","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101570","article-title":"Fucosylation in digestive inflammatory diseases and cancers: from mechanical studies to clinical translation","volume":"12","author":"Duan","year":"2025","journal-title":"Genes Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2816","article-title":"Mesenchymal stem cells: immune evasive, not immune privileged","volume":"32","author":"Ankrum","year":"2014","journal-title":"Nat Biotechnol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.12.447","article-title":"Murine bone marrow stromal progenitor cells elicit an in vivo cellular and humoral alloimmune response","volume":"13","author":"Badillo","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-6-17","article-title":"Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson\u2019s disease","volume":"6","author":"Camp","year":"2009","journal-title":"J Neuroinflamm"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3727\/000000006783981503","article-title":"Immunologic consequences of multiple, high-dose administration of allogeneic mesenchymal stem cells to baboons","volume":"15","author":"Beggs","year":"2006","journal-title":"Cell Transplant"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/stem.217","article-title":"Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells","volume":"27","author":"Zangi","year":"2009","journal-title":"Stem Cells"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12712","article-title":"Immune modulation by mesenchymal stem cells","volume":"53","author":"Jiang","year":"2020","journal-title":"Cell Prolif"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s12015-025-10849-0","article-title":"Improving the wound healing process: pivotal role of mesenchymal stromal\/stem cells and immune cells","volume":"21","author":"Sadeghi","year":"2025","journal-title":"Stem Cell Rev Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2010.08.008","article-title":"Prostaglandin E2 plays a key role in the immunosuppressive properties of adipose and bone marrow tissue-derived mesenchymal stromal cells","volume":"316","author":"Yanez","year":"2010","journal-title":"Exp Cell Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103417","article-title":"Mesenchymal stromal cell infusions of umbilical cord-derived mesenchymal stromal cells in children with recessive dystrophic epidermolysis bullosa (MissionEB): a randomised, double-blind, placebo controlled, crossover, phase 3 trial with an internal phase 1 dose de-escalation phase","volume":"88","author":"Bageta","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/cells8101160","article-title":"Thrombogenic risk induced by intravascular mesenchymal stem cell therapy: current status and future perspectives","volume":"8","author":"Coppin","year":"2019","journal-title":"Cells"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.10.030","article-title":"Natural occurrence of autoantibodies against basement membrane proteins in epidermolysis bullosa","volume":"142","author":"Gostynski","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.151922","article-title":"Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa","volume":"6","author":"Kiritsi","year":"2021","journal-title":"JCI Insight"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.143606","article-title":"Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients","volume":"6","author":"Lee","year":"2021","journal-title":"JCI Insight"},{"key":"B67","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.jid.2020.05.092","article-title":"Intravenous injection of Muse cells as a potential therapeutic approach for epidermolysis bullosa","volume":"141","author":"Fujita","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-015-0271-2","article-title":"Biodistribution, migration and homing of systemically applied mesenchymal stem\/stromal cells","volume":"7","author":"Leibacher","year":"2016","journal-title":"Stem Cell Res Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41392-024-01936-8","article-title":"Pharmacokinetic characteristics of mesenchymal stem cells in translational challenges","volume":"9","author":"Shan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00932-0","article-title":"The secretion profile of mesenchymal stem cells and potential applications in treating human diseases","volume":"7","author":"Han","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2024.110805","article-title":"Unravelling drivers of cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa","volume":"85","author":"Santucci","year":"2024","journal-title":"Hum Immunol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/mt.2008.234","article-title":"Injection of recombinant human type VII collagen corrects the disease phenotype in a murine model of dystrophic epidermolysis bullosa","volume":"17","author":"Remington","year":"2009","journal-title":"Mol Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2020.06.009","article-title":"Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential","volume":"41","author":"Song","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0129-4","article-title":"Glycosylation in health and disease","volume":"15","author":"Reily","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.2001.5230","article-title":"Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: cutaneous lymphocyte antigen","volume":"285","author":"Kieffer","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01878","article-title":"E-selectin ligands in the human mononuclear phagocyte system: implications for infection, inflammation, and immunotherapy","volume":"8","author":"Silva","year":"2017","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104702","article-title":"Central memory and effector memory T cell subsets: function, generation, and maintenance","volume":"22","author":"Sallusto","year":"2004","journal-title":"Annu Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652613","article-title":"The translational relevance of human circulating memory cutaneous lymphocyte-associated antigen positive T cells in inflammatory skin disorders","volume":"12","author":"de Jesus-Gil","year":"2021","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1715937","article-title":"Targeting the cutaneous lymphocyte antigen (CLA) in inflammatory and neoplastic skin conditions","volume":"20","author":"Sernicola","year":"2020","journal-title":"Expert Opin Biol Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1789537\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:17:09Z","timestamp":1777954629000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1789537\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":79,"alternative-id":["10.3389\/fimmu.2026.1789537"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1789537","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"article-number":"1789537"}}